Literature DB >> 7691495

Injectable contraception with depot medroxyprogesterone acetate. Current status.

Andrew M Kaunitz1, Allan Rosenfield2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7691495     DOI： 10.2165/00003495-199345060-00001

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  46 in total

Review 1.  Injectable contraception.

Authors:  A M Kaunitz
Journal:  Clin Obstet Gynecol       Date:  1989-06       Impact factor: 2.190

2.  Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer.

Authors:  M L Gwinn; N C Lee; P H Rhodes; P M Layde; G L Rubin
Journal:  J Clin Epidemiol       Date:  1990       Impact factor: 6.437

3.  Effects of medroxyprogesterone on the liver function and drug metabolism of patients with primary biliary cirrhosis and chronic active hepatitis.

Authors:  E A Sotaniemi; T Hynnynen; J Ahlqvist; J T Ahokas; U Puoskari; I Pelkonen
Journal:  J Med       Date:  1978

4.  Contraceptive use--efficacy study utilizing Depo-Provera administered as an injection once every six months.

Authors:  P C Schwallie; J R Assenzo
Journal:  Contraception       Date:  1972-10       Impact factor: 3.375

Review 5.  The effects of contraceptive use on the initiation and duration of lactation.

Authors:  V H Laukaran
Journal:  Int J Gynaecol Obstet       Date:  1987       Impact factor: 3.561

6.  Medroxyprogesterone acetate as an injectable contraceptive.

Authors:  K R Heber
Journal:  Aust Fam Physician       Date:  1988-03

7.  The protective influence of progestogen only contraception against vaginal moniliasis.

Authors:  M Toppozada; F A Onsy; E Fares; S Amir; S Shaala
Journal:  Contraception       Date:  1979-08       Impact factor: 3.375

8.  Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception.

Authors:  E M Belsey
Journal:  Contraception       Date:  1988-08       Impact factor: 3.375

9.  Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism.

Authors:  J Garza-Flores; D L De la Cruz; V Valles de Bourges; R Sanchez-Nuncio; M Martinez; J L Fuziwara; G Pérez-Palacios
Journal:  Contraception       Date:  1991-07       Impact factor: 3.375

10.  A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: 1. Contraceptive efficacy and side effects. World Health Organization Task Force on Long-Acting Systemic Agents for Fertility Regulation. Special Programme of Research, Development and Research Training in Human Reproduction.

Authors:  S Said; K Omar; S Koetsawang; O Kiriwat; Y Srisatayapan; A Kazi; F Ajmal; H H Wynter; A Pretnar-Darovec; I B Benitez
Journal:  Contraception       Date:  1986-09       Impact factor: 3.375
View more
  2 in total

1.  The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK.

Authors:  I Kyvernitakis; K Kostev; T Nassour; F Thomasius; P Hadji
Journal:  Osteoporos Int       Date:  2016-07-26       Impact factor: 4.507

2.  Association between depot medroxyprogesterone acetate (DMPA), physical activity and bone health.

Authors:  Opeyemi O Babatunde; Jacky J Forsyth
Journal:  J Bone Miner Metab       Date:  2013-08-07       Impact factor: 2.626
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.